For Media: UK Press Releases
This page contains resources intended for journalists only. For media enquiries about our press releases please contact ukmediaenquiries@bayer.com
Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
Chemicals Regulation Directorate lifts restriction for Bayer’s Iblon® fungicide and adds barley to approved crops
Bayer receives MHRA authorisation for new indication of Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option in metastatic hormone-sensitive prostate cancer
Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in Phase III studies
1 - 8of 24 News
1 - 8of 24 News